

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

Hs 695T

RRID:CVCL_0851

Type: Cell Line

Proper Citation

RRID:CVCL_0851

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0851

Proper Citation: RRID:CVCL_0851

Description: Cell line Hs 695T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: [PMID:478563](#), [PMID:6500159](#), [PMID:6988327](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hs 695T

Synonyms: Hs 695.T, Hs-695-T, HS-695T, HS 695T, Hs695T, HS695T, Hs695

Cross References: CLO:CLO_0004053, EFO:EFO_0006588, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-137, BCRC:60268, BioGRID_ORCS_Cell_line:652, BioSample:SAMN03470910, BioSample:SAMN10988229, cancercellines:CVCL_0851, Cell_Model_Passport:SIDM01561, ChEMBL-Cells:ChEMBL4523540, ChEMBL-Targets:ChEMBL4523571, CLS:300211, Cosmic:933004, DepMap:ACH-000799, EGA:EGAS00001000610, GEO:GSM206512, GEO:GSM274686, GEO:GSM887108, GEO:GSM888179, IARC_TP53:30057,

LiGeA:CCLE_227, PharmacDB:Hs695T_586_2019, Progenetix:CVCL_0851, PubChem_Cell_line:CVCL_0851, Wikidata:Q54895895

ID: CVCL_0851

Record Creation Time: 20220427T220608+0000

Record Last Update: 20260920T004108+0000

Ratings and Alerts

No rating or validation information has been found for Hs 695T.

No alerts have been found for Hs 695T.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.